Previous close | 9.51 |
Open | 9.51 |
Bid | 9.36 x 2600 |
Ask | 9.39 x 1900 |
Day's range | 9.22 - 9.56 |
52-week range | 4.97 - 16.75 |
Volume | |
Avg. volume | 5,727,185 |
Market cap | 2.26B |
Beta (5Y monthly) | 0.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.60 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 13.00 |
On May 14, 2024, Blake Borgeson, Director at Recursion Pharmaceuticals Inc (NASDAQ:RXRX), executed a sale of 20,054 shares of the company.
BioHive-2, an NVIDIA DGX SuperPOD with NVIDIA DGX H100 systems, ranked #35 in the TOP500 list of the most powerful supercomputers in the world across all industries as of May 2024.SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVID
Recursion Pharmaceuticals ( NASDAQ:RXRX ) First Quarter 2024 Results Key Financial Results Revenue: US$13.8m (up 14...